| Basics |
PTC Therapeutics, Inc.
PTC Therapeutics Inc is a biopharmaceutical company. It is focused on the discovery and development of orally administered, proprietary small-molecule drugs that target post-transcriptional control processes.
|
| IPO Date: |
June 20, 2013 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$3.79B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.86 | 2.70%
|
| Avg Daily Range (30 D): |
$0.86 | 1.95%
|
| Avg Daily Range (90 D): |
$1.10 | 2.36%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.71M |
| Avg Daily Volume (30 D): |
1.04M |
| Avg Daily Volume (90 D): |
.82M |
| Trade Size |
| Avg Trade Size (Sh.): |
93 |
| Avg Trade Size (Sh.) (30 D): |
57 |
| Avg Trade Size (Sh.) (90 D): |
55 |
| Institutional Trades |
| Total Inst.Trades: |
6,927 |
| Avg Inst. Trade: |
$2.38M |
| Avg Inst. Trade (30 D): |
$3.38M |
| Avg Inst. Trade (90 D): |
$3.28M |
| Avg Inst. Trade Volume: |
.06M |
| Avg Inst. Trades (Per Day): |
2 |
| Market Closing Trades |
| Avg Closing Trade: |
$3.76M |
| Avg Closing Trade (30 D): |
$8.6M |
| Avg Closing Trade (90 D): |
$7.81M |
| Avg Closing Volume: |
99.43K |
|
|
|
|
| Financials |
| |
TTM |
Q1 2025 |
Q3 2024 |
|
Basic EPS
|
|
$11.09
|
$-1.39
|
|
Diluted EPS
|
|
$10.04
|
$-1.39
|
|
Revenue
|
$
|
$ 1.18B
|
$ 196.79M
|
|
Gross Profit
|
$
|
$
|
$
|
|
Net Income / Loss
|
$
|
$ 866.56M
|
$ -106.65M
|
|
Operating Income / Loss
|
$
|
$ 970.23M
|
$ -54.51M
|
|
Cost of Revenue
|
$
|
$
|
$
|
|
Net Cash Flow
|
$
|
$ 695.15M
|
$ -137.29M
|
|
PE Ratio
|
|
|
|
|
